北大医药
(000788)
| 流通市值：40.35亿 | | | 总市值：40.35亿 |
| 流通股本：5.96亿 | | | 总股本：5.96亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 502,359,685.42 | 2,060,014,642.65 | 1,534,330,245.12 | 1,008,128,208.1 |
| 营业收入 | 502,359,685.42 | 2,060,014,642.65 | 1,534,330,245.12 | 1,008,128,208.1 |
| 二、营业总成本 | 449,551,963.27 | 1,856,768,030.42 | 1,371,419,826.74 | 897,060,160.66 |
| 营业成本 | 382,158,273.99 | 1,507,540,914.04 | 1,108,500,741.03 | 716,847,403.96 |
| 税金及附加 | 2,491,717.2 | 10,904,583.93 | 8,032,811.75 | 5,060,540.19 |
| 销售费用 | 37,062,146.95 | 202,183,825.02 | 168,872,186.41 | 121,398,899.05 |
| 管理费用 | 23,406,614.27 | 109,751,555.25 | 73,033,945.27 | 44,958,871.88 |
| 研发费用 | 5,179,004.74 | 27,041,662.02 | 13,294,511.08 | 9,226,381.24 |
| 财务费用 | -745,793.88 | -654,509.84 | -314,368.8 | -431,935.66 |
| 其中:利息费用 | 1,855,384.78 | 4,168,555.1 | 2,421,511.97 | 1,779,784.41 |
| 其中:利息收入 | 3,831,511.71 | 5,025,465.72 | 2,880,150.25 | 2,309,706.48 |
| 加:投资收益 | - | -235,738.82 | - | - |
| 资产处置收益 | - | 185,840.72 | 185,840.72 | 185,840.72 |
| 资产减值损失(新) | -5,916.05 | -46,250,443.11 | -4,282,872.37 | -4,144,370.82 |
| 信用减值损失(新) | -933,768.69 | 11,529,003.17 | 2,203,524.12 | 1,289,230.04 |
| 其他收益 | 1,113,371.75 | 3,521,782.22 | 2,914,977.22 | 1,957,107.85 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 52,981,409.16 | 171,997,056.41 | 163,931,888.07 | 110,355,855.23 |
| 加:营业外收入 | 1,654,364.32 | 1,160,586.09 | 176,145.37 | 120,019.3 |
| 减:营业外支出 | 54,741.02 | 804,590.68 | 796,552.43 | 781,558.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 54,581,032.46 | 172,353,051.82 | 163,311,481.01 | 109,694,316.46 |
| 减:所得税费用 | 8,940,482.25 | 34,360,447.09 | 32,997,749.93 | 22,901,683.33 |
| 六、净利润 | 45,640,550.21 | 137,992,604.73 | 130,313,731.08 | 86,792,633.13 |
| 持续经营净利润 | 45,640,550.21 | 137,992,604.73 | 130,313,731.08 | 86,792,633.13 |
| 归属于母公司股东的净利润 | 45,640,550.21 | 137,992,604.73 | 130,364,988.72 | 86,825,395.85 |
| 少数股东损益 | - | - | -51,257.64 | -32,762.72 |
| (一)基本每股收益 | 0.08 | 0.23 | 0.22 | 0.15 |
| (二)稀释每股收益 | 0.08 | 0.23 | 0.22 | 0.15 |
| 九、综合收益总额 | 45,640,550.21 | 137,992,604.73 | 130,313,731.08 | 86,792,633.13 |
| 归属于母公司股东的综合收益总额 | 45,640,550.21 | 137,992,604.73 | 130,364,988.72 | 86,825,395.85 |
| 归属于少数股东的综合收益总额 | - | - | -51,257.64 | -32,762.72 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-26 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |